menu
    • menu
    [{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Fleroxacin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Fleroxacin

    Menu

    Fleroxacin

    DEVELOPMENTS

    INTERMEDIATES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novo Nordisk

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fleroxacin

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk Successfully Completes AM833 Phase 2 Trial and Phase 1 Combination Trial with AM833 and Semagluti...

                            Details : The 26-week blinded phase 2 monotherapy trial with AM833 investigated safety, tolerability and efficacy for weight management in 706 people with obesity or overweight with at least one weight-related comorbidity.

                            Brand Name : AM833

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            June 18, 2020

                            Lead Product(s) : Fleroxacin

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth